IGI Logo

Themis Medicare is currently trading at Rs. 1357.00, up by 7.60 points or 0.56% from its previous closing of Rs. 1349.40 on the BSE.

The scrip opened at Rs. 1374.60 and has touched a high and low of Rs. 1401.35 and Rs. 1351.00 respectively. So far 1184 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1434.25 on 16-Dec-2022 and a 52 week low of Rs. 692.00 on 20-Jun-2022.

Last one week high and low of the scrip stood at Rs. 1410.60 and Rs. 1323.60 respectively. The current market cap of the company is Rs. 1264.12 crore.

The promoters holding in the company stood at 67.18%, while Institutions and Non-Institutions held 0.03% and 32.80% respectively.

Themis Medicare has launched a novel transdermal Estradiol spray Lenzetto in the Indian market for treatment of Menopausal Symptoms. Lenzetto has a clinical experience in 40 countries and is approved by USFDA & EMA for the treatment of Menopausal Symptoms. Lenzetto is manufactured in Europe by Gedeon Richter, The Global Innovators in Women’s Health.

Lenzetto a novel transdermal estradiol with Metered Dose Transdermal Spray (MDTS) Technology) delivers therapeutic doses of estradiol to the skin, using a metering pump containing 1.53 mg/spray estradiol hemihydrate. Transdermal delivery of estrogen is well established in clinical practice and ensures sufficient serum estradiol levels to alleviate Menopausal Symptoms like hot flashes, night sweats etc. at lower overall estradiol exposure while avoiding some of the consequences of high hepatic exposure and first-pass metabolism.

Themis Medicare is a research-based pharmaceutical company specializing in manufacture of a wide range of products for application areas like Pain Management, Critical Care and Anti-Infectives.